BioStock: Aptahem provides an operational update

Report this content

Aptahem is nudging closer to its biggest milestone as a listed biotech company – the  first clinical studies with Apta-1, a drug candidate designed to serve as an emergency treatment for sepsis and the life-threatening conditions that can arise from it. The latest sign that the company activities are simmering beneath the surface was when an application for study initiation was recently submitted to the authorities. BioStock contacted CEO Mikael Lindstam for an operational update.

Read the full interview with Mikael Lindstam at

This is a press release from BioStock - Connecting Innovation & Capital.


Documents & Links

Quick facts

BioStock: Aptahem provides an operational update
Tweet this